查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1985863

心臟生物标记市场规模、份额和趋势分析报告：按类型、应用、最终用途、地区和细分市场划分 - 预测，2026-2033 年

Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Troponin, Creatine kinase - MB, Myoglobin, BNP and NT-proBNP), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

心臟生物标记市场概述

全球心臟生物标记市场预计到 2025 年价值 208.1 亿美元，预计到 2033 年将达到 493.1 亿美元，2026 年至 2033 年的复合年增长率为 11.5%。

心血管疾病（如急性冠状动脉症候群、心肌梗塞和心臟衰竭）的日益普遍推动了这一市场的发展，导致对早期准确诊断的需求增加。

高敏肌钙蛋白检测和多标记检测技术的进步改善了临床决策和患者预后。此外，就地检验的日益普及、有利的报销机制以及老年人口不断增长（老年人患心臟病的风险较高）等因素，持续推动着全球市场的扩张。

心血管疾病是全球主要死因之一。根据世界卫生组织（WHO）2023年的调查，每年约有1,790万人死于心臟病。老化、肥胖、糖尿病和高血压等因素持续加剧这些疾病的盛行率，导致越来越多的人面临心臟病发作和心臟衰竭的风险。随着心血管疾病负担的加重，早期发现、准确诊断和有效病患监测的需求变得特别迫切。心臟生物标记在此发挥至关重要的作用。肌钙蛋白、肌酸激酶-MB（CK-MB）和肌红蛋白等生物标记对于检测心肌损伤和评估疾病严重程度至关重要，有助于指导治疗决策。

对即时检测（POC​​）心臟检测套组日益增长的需求预计将进一步推动心臟生物标记市场的成长。传统上，心血管疾病的诊断依赖中心检查室的检测，这需要专门的设备和训练有素的人员。这些传统系统可能导致诊断和治疗的延误，尤其是在急性情况下，例如疑似胸痛或心肌梗塞的急诊就诊。此类延误可能造成严重的临床后果，因为及时识别心臟事件对于启动干预措施和提高患者存活率至关重要。即时检测心臟检测套组能够在患者照护场所（例如急诊室、循环系统诊所和居家医疗机构）直接实现快速诊断结果和及时决策。肌钙蛋白、脑钠肽 (BNP) 和肌酸激酶-MB (CK-MB) 等关键生物标记现在可以在临床环境中进行测量，使临床医生能够更快地做出治疗决策。例如，即时检测肌钙蛋白 (cTn) 通常在 10 到 20 分钟内即可提供结果。

新型生物标记，例如可溶性肿瘤抑制因子-2 (sST2)、心臟脂肪酸结合蛋白质(H-FABP)、半乳糖凝集素-3 和生长分化因子-15 (GDF-15)，因其潜在的临床效用而备受关注。例如，MDPI 于 2025 年 8 月发表的一项研究报告称，GDF-15、sST2、suPAR 和 H-FABP 等生物标记在多种心血管疾病中显示出良好的应用前景。

这些新型生物标记不仅反映了心血管生理的各个方面，而且有望改善早期诊断和治疗反应监测。高灵敏度检测和奈米技术感测器等技术的进步，进一步提高了在极低浓度下检测这些生物标记的能力，从而能够更快、更准确地做出临床决策。此外，透过将多种生物标记组合成一个检测组合，临床医生可以更全面地了解患者的心血管状态，从而实现更个人化和精准的治疗方案。随着研究的深入和更多证据的出现，这些新型心臟生物标记有望在改善心臟病患者的预后方面发挥关键作用。

目录

第一章：调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场历史及展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势与展望
  • 市场动态
  • 商业环境分析
    • PESTLE分析
    • 波特五力分析
  • 新冠疫情影响分析

第四章 按类型进行业务分析

  • 心臟生物标记市场：按类型分類的波动分析，2025-2033年
  • 肌钙蛋白
  • CK-MB
  • 肌红蛋白
  • BNP・NT-proBNP
  • 其他的

第五章 应用业务分析

  • 心臟生物标记市场：基于应用领域的波动分析，2025-2033年
  • 急性冠状动脉症候群
  • 心肌梗塞
  • 郁血性心臟衰竭
  • 其他的

第六章 依最终用途进行业务分析

  • 心臟生物标记市场：以最终用途分類的波动分析，2025-2033年
  • 实验室检测
  • 即时检测

第七章：按地区分類的业务分析

  • 区域市场概览
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 公司分类
  • 策略规划
    • 获得
    • 合伙
    • 新平台推出
    • 其他的
  • 公司简介/上市资讯
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers
    • Danaher
    • F. Hoffmann-La Roche Ltd
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd
    • Creative Diagnostics
    • Life Diagnostics
Product Code: GVR-1-68038-083-5

Cardiac Biomarkers Market Summary

The global cardiac biomarkers market size was estimated at USD 20.81 billion in 2025 and is expected to reach USD 49.31 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The market is driven by the rising prevalence of cardiovascular diseases such as acute coronary syndrome, myocardial infarction, and heart failure, increasing the demand for early and accurate diagnosis.

Advancements in high-sensitivity troponin assays and multi-marker testing have improved clinical decision-making and patient outcomes. In addition, expanding use of point-of-care testing, supportive reimbursement frameworks, and an aging population with higher cardiac risk continue to support market expansion globally.

Cardiovascular diseases are one of the major causes of death globally. According to the World Health Organization (WHO) survey in 2023, it was stated that approximately 17.9 million deaths due to cardiac disorders were reported each year. The prevalence of these conditions continues to rise due to an aging population, obesity, diabetes, and hypertension, leading to an increasing number of individuals at risk of heart attack or heart failure. The growing burden of cardiovascular diseases has created a critical need for early detection, accurate diagnosis, and effective patient monitoring. This is where cardiac biomarkers play a vital role. Biomarkers such as troponin, Creatine Kinase-MB (CK-MB), and myoglobin are essential for detecting myocardial injury and assessing disease severity and therefore help in making treatment decisions.

The rising demand for point-of-care (POC) cardiac testing kits is further expected to propel the growth in the cardiac biomarkers Market. Traditionally, the diagnosis of cardiovascular diseases relied on centralized laboratory testing, which requires specialized instruments and trained personnel. These conventional systems can delay diagnosis and treatment, particularly in acute settings such as emergency department admissions for chest pain or suspected myocardial infarction. Such delays can have serious clinical consequences, as timely identification of cardiac events is critical for initiating interventions and improving patient survival rates. POC cardiac testing kits enable quick diagnostic results for making timely decisions directly at the site of patient care, including emergency rooms, cardiology clinics, and in-home-based settings. Key biomarkers such as troponin, natriuretic peptide (BNP), and creatine kinase-MB (CK-MB) are now measurable at the point of care, allowing clinicians to make faster treatment decisions. For instance, POC cTn tests typically provide results within 10 to 20 minutes.

Emerging biomarkers, including soluble suppression of tumorigenicity-2 (sST2), heart-type fatty acid-binding protein (H-FABP), Galectin-3, and growth differentiation factor-15 (GDF-15), are gaining attention for their potential clinical utility. For instance, a study published by MDPI in August 2025 reported that the biomarkers GDF-15, sST2, suPAR, and H-FABP demonstrated promising potential across a range of cardiovascular diseases.

These novel biomarkers not only reflect different aspects of cardiovascular physiology but also offer the potential to improve early diagnosis and monitoring of treatment response. Advances in technology, including high-sensitivity assays and nanotechnology-based sensors, have further enhanced the ability to detect these biomarkers at very low concentrations, enabling faster and more accurate clinical decision-making. In addition, combining multiple biomarkers into panels allows clinicians to gain a more comprehensive understanding of a patient's cardiovascular status, moving toward more personalized and precise approaches to care. As research continues and more evidence emerges, these novel cardiac biomarkers are expected to play an important role in improving outcomes for patients with heart disease.

Global Cardiac Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the cardiac biomarkers market based on type, application, end use, and region.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Troponin
  • CK-MB
  • Myoglobin
  • BNP and NT-proBNP
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Testing
  • Point of Care Testing
  • Regional Outlook (Revenue, USD Million, 2021-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Application and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing prevalence of cardiovascular diseases
      • 3.3.1.2. Rising demand for point of care (POC) cardiac testing kits
      • 3.3.1.3. Increasing focus on innovation and development of novel cardiac biomarkers
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Stringent regulatory barriers
      • 3.3.2.2. Lack of specificity in cardiac biomarkers
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Cardiac Biomarkers Market: Type Movement Analysis, 2025 & 2033
  • 4.2. Troponin
    • 4.2.1. Troponin market, 2021 - 2033 (USD Million)
  • 4.3. CK-MB
    • 4.3.1. CK-MB market, 2021 - 2033 (USD Million)
  • 4.4. Myoglobin
    • 4.4.1. Myoglobin market, 2021 - 2033 (USD Million)
  • 4.5. BNP and NT-proBNP
    • 4.5.1. BNP and NT-proBNP market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Cardiac Biomarkers Market: Application Movement Analysis, 2025 & 2033
  • 5.2. Acute Coronary Syndrome
    • 5.2.1. Acute coronary syndrome market, 2021 - 2033 (USD Million)
  • 5.3. Myocardial Infarction
    • 5.3.1. Myocardial infarction market, 2021 - 2033 (USD Million)
  • 5.4. Congestive Heart Failure
    • 5.4.1. Congestive heart failure market, 2021 - 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. Cardiac Biomarkers Market: End Use Movement Analysis, 2025 & 2033
  • 6.2. Lab Testing
    • 6.2.1. Lab testing Market, 2021 - 2033 (USD Million)
  • 6.3. POC testing
    • 6.3.1. POC testing Market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Germany Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Competitive Scenario
    • 7.3.3. UK
      • 7.3.3.1. UK Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Competitive Scenario
    • 7.3.4. France
      • 7.3.4.1. France Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Competitive Scenario
    • 7.3.5. Italy
      • 7.3.5.1. Italy Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Competitive Scenario
    • 7.3.6. Spain
      • 7.3.6.1. Spain Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Competitive Scenario
    • 7.4.6. Australia
      • 7.4.6.1. Australia Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Competitive Scenario
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2. Key Country Dynamics
    • 7.5.3. Regulatory Framework
    • 7.5.4. Competitive Scenario
    • 7.5.5. Brazil
      • 7.5.5.1. Brazil Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.5.2. Key Country Dynamics
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Competitive Scenario
    • 7.5.6. Argentina
      • 7.5.6.1. Argentina Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.6.2. Key Country Dynamics
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. Acquisition
    • 8.2.2. Collaborations
    • 8.2.3. New Platform Launches
    • 8.2.4. Others
  • 8.3. Company Profiles/Listing
    • 8.3.1. Abbott
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Quidel Corporation
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Siemens Healthineers
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Danaher
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. F. Hoffmann-La Roche Ltd
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. bioMerieux SA
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Bio-Rad Laboratories, Inc.
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Randox Laboratories Ltd
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Creative Diagnostics
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Life Diagnostics
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 Global Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 3 Global Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 4 Global Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 5 Global Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 6 North America Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 7 North America Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 8 North America Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 9 North America Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 10 U.S Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 11 U.S Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 12 U.S Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 13 U.S Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 15 Canada Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 16 Canada Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 17 Canada Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 19 Mexico Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 20 Mexico Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 21 Mexico Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 22 Europe Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 23 Europe Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 24 Europe Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 25 Europe Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 26 UK Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 27 UK Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 28 UK Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 29 UK Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 30 Germany Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 31 Germany Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 32 Germany Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 33 Germany Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 34 France Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 35 France Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 36 France Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 37 France Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 38 Italy Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 39 Italy Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 40 Italy Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 41 Italy Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 42 Spain Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 43 Spain Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 44 Spain Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 45 Spain Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 46 Denmark Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 47 Denmark Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 48 Denmark Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 49 Denmark Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 50 Sweden Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 51 Sweden Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 52 Sweden Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 53 Sweden Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 54 Norway Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 55 Norway Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 56 Norway Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 57 Norway Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 62 Japan Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 63 Japan Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 64 Japan Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 65 Japan Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 66 China Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 67 China Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 68 China Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 69 China Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 70 India Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 71 India Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 India Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 73 India Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 74 Australia Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 75 Australia Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 76 Australia Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 77 Australia Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 78 South Korea Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 79 South Korea Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 80 South Korea Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 81 South Korea Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 82 Latin America Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 83 Latin America Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 84 Latin America Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 85 Latin America Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 86 Brazil Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 87 Brazil Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 Brazil Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 89 Brazil Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 90 Argentina Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 91 Middle East & Africa Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 92 Middle East & Africa Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 Middle East & Africa Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 94 Middle East & Africa Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 95 South Africa Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 96 South Africa Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 97 South Africa Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 98 South Africa Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 99 Saudi Arabia Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 100 Saudi Arabia Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 101 Saudi Arabia Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 102 Saudi Arabia Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)
  • Table 103 UAE Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 104 UAE Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 105 UAE Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 106 UAE Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million
  • Table 107 Kuwait Cardiac Biomarkers Market, by Region, 2021 - 2033 (USD Million)
  • Table 108 Kuwait Cardiac Biomarkers Market, by Type, 2021 - 2033 (USD Million)
  • Table 109 Kuwait Cardiac Biomarkers Market, by Application, 2021 - 2033 (USD Million)
  • Table 110 Kuwait Cardiac Biomarkers Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cardiac biomarkers: Market outlook
  • Fig. 8 Cardiac biomarkers: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Cardiac biomarkers market driver impact
  • Fig. 13 Cardiac biomarkers market restraint impact
  • Fig. 14 Cardiac biomarkers market strategic initiatives analysis
  • Fig. 15 Cardiac biomarkers market: Type movement analysis
  • Fig. 16 Cardiac biomarkers market: Type outlook and key takeaways
  • Fig. 17 Troponin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 CK-MB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Myoglobin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 BNP and NT-proBNP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiac biomarkers market: Application movement analysis
  • Fig. 23 Cardiac biomarkers market: Application outlook and key takeaways
  • Fig. 24 Acute coronary syndrome market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myocardial infarction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Congestive heart failure market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiac biomarkers market: End use movement analysis
  • Fig. 29 Cardiac biomarkers market: End use outlook and key takeaways
  • Fig. 30 Laboratory testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Point of care testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pain management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Cancer therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Vaccine delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Other end use market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Global cardiac biomarkers market: Regional movement analysis
  • Fig. 37 Global cardiac biomarkers market: Regional outlook and key takeaways
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)